Document Detail


The effect of prior bisphosphonate exposure on the treatment response to teriparatide in clinical practice.
MedLine Citation:
PMID:  17938845     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Our objective was to determine the effect of prior bisphosphonate exposure on the treatment response to teriparatide. All patients started on teriparatide in our hospital are entered into a database. All patients who had at least 12 months' treatment were identified. Patients were divided into two groups depending on whether or not they had prior bisphosphonate exposure, and the response to teriparatide was compared using procollagen of type 1 N-terminal propeptide (P1NP) and bone mineral density (BMD). Fifty-two patients had been treated for at least 12 months, 38 with prior bisphosphonate exposure and 14 without. The mean duration of bisphosphonate treatment was 67 months, discontinued a mean of 1 month previously. P1NP increased significantly at 3 and 6 months in both groups. However, those without previous bisphosphonate treatment had a higher baseline P1NP (49 vs. 30 microg/L, P<0.01), and this remained higher at 3 months (109 vs. 71 microg/L, P=0.10) and 6 months (183 vs. 126 microg/L, P=0.06), although the difference was not significant. In the prior bisphosphonate and bisphosphonate naive groups, respectively, the change in spinal BMD was 9.0% and 7.8% (P=0.54) at 12 months and 9.8% and 6.1% (P=0.30) at 18 months. The respective change in hip BMD was 1.0% and -0.3% (P=0.36) at 12 months and 2.8% and 1.3% (P=0.44) at 18 months. There was a trend toward a smaller but still significant increase in P1NP in response to teriparatide in bisphosphonate-treated patients. Although this suggests a blunting of the anabolic effects, in our clinic population this did not result in a reduction in BMD gain.
Authors:
Edward T Middleton; Sue A Steel; Sheelagh M Doherty
Related Documents :
19469885 - Long-term effects of magnesium carbonate on coronary artery calcification and bone mine...
2981045 - Coherence treatment of postmenopausal osteoporosis with growth hormone and calcitonin.
12040205 - Craniomaxillofacial fibrous dysplasia.
6619125 - Aging and 3,4-diaminopyridine alter synaptosomal calcium uptake.
19642225 - Efficacy of additional ablation of complex fractionated atrial electrograms for cathete...
18637605 - Comparison of percutaneous dilatational tracheostomy with surgical tracheostomy.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article     Date:  2007-10-16
Journal Detail:
Title:  Calcified tissue international     Volume:  81     ISSN:  0171-967X     ISO Abbreviation:  Calcif. Tissue Int.     Publication Date:  2007 Nov 
Date Detail:
Created Date:  2007-11-08     Completed Date:  2008-02-19     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7905481     Medline TA:  Calcif Tissue Int     Country:  United States    
Other Details:
Languages:  eng     Pagination:  335-40     Citation Subset:  IM    
Affiliation:
Centre for Metabolic Bone Disease, Hull Royal Infirmary, 220-236 Anlaby Road, Hull HU3 2RW, UK. etmiddleton@doctors.org.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Biological Markers / analysis,  metabolism
Bone Density / drug effects,  physiology
Bone Density Conservation Agents / administration & dosage*
Diphosphonates / administration & dosage*
Dose-Response Relationship, Drug
Drug Interactions / physiology
Female
Femur Neck / drug effects,  metabolism,  physiopathology
Humans
Middle Aged
Osteoporosis, Postmenopausal / drug therapy*,  metabolism,  physiopathology
Peptide Fragments / analysis,  drug effects,  metabolism
Procollagen / analysis,  drug effects,  metabolism
Spine / drug effects,  metabolism,  physiopathology
Teriparatide / administration & dosage*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Bone Density Conservation Agents; 0/Diphosphonates; 0/Peptide Fragments; 0/Procollagen; 0/procollagen Type I N-terminal peptide; 52232-67-4/Teriparatide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Is there a difference in patient and physician quality of life evaluation in pelvic organ prolapse?
Next Document:  Duodeno-jejunal junction: a histoanatomical study with the concept of the existence of an "anatomica...